Publicacions en què col·labora amb Vicente Soriano Vázquez (11)

2015

  1. Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study

    PLoS ONE, Vol. 10, Núm. 10

  2. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

  3. TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfected patients

    Journal of Clinical Virology, Vol. 65, pp. 62-67

2014

  1. European mitochondrial haplogroups are not associated with hepatitis C virus (HCV) treatment response in HIV/HCV-coinfected patients

    HIV Medicine, Vol. 15, Núm. 7, pp. 425-430

  2. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

  3. PPARγ2 Pro12Ala polymorphism is associated with sustained virological response in HIV/HCV-coinfected patients under HCV therapy

    Journal of Acquired Immune Deficiency Syndromes, Vol. 67, Núm. 2, pp. 113-119

2013

  1. Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients

    AIDS, Vol. 27, Núm. 2, pp. 163-173

  2. HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy

    AIDS, Vol. 27, Núm. 8, pp. 1231-1238

  3. IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients

    Journal of Viral Hepatitis, Vol. 20, Núm. 5, pp. 358-366

  4. Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: Role of antiretroviral therapy

    AIDS, Vol. 27, Núm. 2, pp. 181-189

2008

  1. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens

    HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313